Neurotoxin Compositions for Treating Gastroparesis
Summary
USPTO published patent application US20260091094A1 disclosing neurotoxin compositions and methods for treating gastroparesis. Inventors Gregory F. Brooks and Eric Carter filed the application on December 9, 2025, under application number 19413766. The publication constitutes prior art as of April 2, 2026.
What changed
USPTO published patent application US20260091094A1 (Kind A1) on April 2, 2026, disclosing neurotoxin compositions for treating gastroparesis. The application (No. 19413766) was filed December 9, 2025, by inventors Gregory F. Brooks and Eric Carter. CPC classifications indicate therapeutic protein preparations (A61K 38/4893), pharmaceutical compositions (A61K 9/0019), and gastroparesis treatments (A61P 1/14).\n\nThis is a routine patent publication establishing priority date and placing the invention in the public record as prior art. Pharmaceutical companies and healthcare researchers developing gastroparesis treatments should conduct freedom-to-operate analyses. Entities investing in this therapeutic area should review the claims to assess potential IP conflicts with existing or future patent portfolios.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NEUROTOXIN COMPOSITIONS FOR USE IN TREATING GASTROPARESIS
Application US20260091094A1 Kind: A1 Apr 02, 2026
Inventors
Gregory F. Brooks, Eric Carter
Abstract
Disclosed herein are compositions and methods for use in treating gastroparesis.
CPC Classifications
A61K 38/4893 A61K 9/0019 A61P 1/14
Filing Date
2025-12-09
Application No.
19413766
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.